Record Details

Royal jelly significantly alters inflammasome pathways in patients with chronic hepatitis B

NOPR - NISCAIR Online Periodicals Repository

View Archive Info
 
 
Field Value
 
Title Royal jelly significantly alters inflammasome pathways in patients with chronic hepatitis B
 
Creator Bahaaldin-beygi, Morteza
Kariminik, Ashraf
Arababadi, Mohammad Kazemi
 
Subject Apis mellifera
Bee products
Gene expression
 
Description 875-579
Royal jelly (RJ) plays immunomodulatory role in humans.
Further, role played by inflammasomes against hepatitis B virus
(HBV) and involvement in its complications are well known.
Here, we evaluated the effects of RJ on the relative expression of
apoptosis associated with speck-like protein (ASC), node like
receptor (NLR) family pyrin domain containing 1 (NLRP1),
NLRP3, S100 calcium binding protein A4 (S100A4), and
S100A9, as the immune system-related molecules in patients with
chronic hepatitis B infection. RJ was administrated for 1 month
(@1 g/day), to the patients with chronic hepatitis B infection. The
relative expressions of ASC, NLRP1, NLRP3, S100A4 and
S100A9 were evaluated using Real-Time PCR. The results
showed that RJ increased the expression of ASC, but decreased
the expression of NLRP1 in the patients with chronic hepatitis B
infection. Relative expressions of NLRP3, S100A4, and S100A9
were not altered following treatment with RJ. There were no
significant differences between men and women regarding the
relative expression of the molecules. The results suggest that RJ
can modulate immune responses via downregulation of NLRP1.
The roles played by ASC in other pathways suggest that the
upregulation of ASC could be associated with its
immunomodulatory potential.
 
Date 2022-10-25T08:56:41Z
2022-10-25T08:56:41Z
2022-11
 
Type Article
 
Identifier 0975-1009 (Online); 0019-5189 (Print)
http://nopr.niscpr.res.in/handle/123456789/60728
https://doi.org/10.56042/ijeb.v60i11.60264
 
Language en
 
Source NIScPR-CSIR, India